Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options-a mini-review
S Ali, JM Garcia - Gerontology, 2014 - karger.com
By the year 2050, individuals over the age of 65 years will comprise 20% of the US
population. Loss of muscle mass and strength is common in this age group and it is …
population. Loss of muscle mass and strength is common in this age group and it is …
Pharmacologic options for the treatment of sarcopenia
JE Morley - Calcified tissue international, 2016 - Springer
Sarcopenia is now clinically defined as a loss of muscle mass coupled with functional
deterioration (either walking speed or distance or grip strength). Based on the FRAX studies …
deterioration (either walking speed or distance or grip strength). Based on the FRAX studies …
[PDF][PDF] Fat‐free muscle mass in magnetic resonance imaging predicts acute‐on‐chronic liver failure and survival in decompensated cirrhosis
M Praktiknjo, M Book, J Luetkens, A Pohlmann… - …, 2018 - Wiley Online Library
Muscle mass seems to be a prognostic marker in patients with liver cirrhosis. However,
reported methods to quantify muscle mass are heterogeneous, consented cutoff values are …
reported methods to quantify muscle mass are heterogeneous, consented cutoff values are …
Regulation of muscle mass by follistatin and activins
Myostatin is a TGF-β family member that normally acts to limit skeletal muscle mass.
Follistatin is a myostatin-binding protein that can inhibit myostatin activity in vitro and …
Follistatin is a myostatin-binding protein that can inhibit myostatin activity in vitro and …
Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles
A Biscans, J Caiazzi, N McHugh, V Hariharan… - Molecular Therapy, 2021 - cell.com
Oligonucleotide therapeutics hold promise for the treatment of muscle-and heart-related
diseases. However, oligonucleotide delivery across the continuous endothelium of muscle …
diseases. However, oligonucleotide delivery across the continuous endothelium of muscle …
Genetics of athletic performance
EA Ostrander, HJ Huson… - Annual review of …, 2009 - annualreviews.org
Performance enhancing polymorphisms (PEPs) are examples of natural genetic variation
that affect the outcome of athletic challenges. Elite athletes, and what separates them from …
that affect the outcome of athletic challenges. Elite athletes, and what separates them from …
The structure of myostatin: follistatin 288: insights into receptor utilization and heparin binding
JN Cash, CA Rejon, AC McPherron, DJ Bernard… - The EMBO …, 2009 - embopress.org
Myostatin is a member of the transforming growth factor‐β (TGF‐β) family and a strong
negative regulator of muscle growth. Here, we present the crystal structure of myostatin in …
negative regulator of muscle growth. Here, we present the crystal structure of myostatin in …
Forum on bone and skeletal muscle interactions: summary of the proceedings of an ASBMR workshop
Annual costs are enormous for musculoskeletal diseases such as osteoporosis and
sarcopenia and for bone and muscle injuries, costing billions annually in health care …
sarcopenia and for bone and muscle injuries, costing billions annually in health care …
Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance
S Busquets, M Toledo, M Orpí, D Massa… - Journal of cachexia …, 2012 - Springer
Background Cachexia is a multiorganic syndrome associated with cancer, characterized by
body weight loss, muscle and adipose tissue wasting and inflammation. Methods The aim of …
body weight loss, muscle and adipose tissue wasting and inflammation. Methods The aim of …
Myostatin: more than just a regulator of muscle mass
The presence of sufficient skeletal muscle mass is of paramount importance for body
function and the myostatin cascade is known to inhibit muscle growth in mammals. In …
function and the myostatin cascade is known to inhibit muscle growth in mammals. In …